WARF: P130007US02

Vitamin D Analogs “WT-51” and “WT-52” Boost Bone and Skin Health


Hector DeLuca, Lori Plum, Rafal Barycki, Margaret Clagett-Dame

The Wisconsin Alumni Research Foundation (WARF) is helping develop new 19-nor vitamin D compounds that are up to 10 times more potent in promoting cell differentiation.
OVERVIEWVitamin D (1,25-dihydroxyvitamin D3) is a highly potent regulator of calcium homeostasis and plays an established role in cellular differentiation. An important class of vitamin D analogs, the 19-nor-vitamin D compounds, shows high cell differentiation activity and minimal calcemic activity, making these analogs excellent candidates for a variety of pharmaceutical uses.
THE INVENTIONUW–Madison researchers have developed two new vitamin D3 analogs, (22E)-(24R/S)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3, known as WT-51 and WT-52. These compounds show activity similar to that of the native hormone in stimulating intestinal calcium transport, but are up to 10 times more potent in promoting cell differentiation and gene transcription.
  • Treating osteoporosis, osteomalacia and osteopenia
  • Improving bone strength and density
  • Treating skin issues such as psoriasis, wrinkles, dryness and acne
  • Potential anti-cancer agent, especially against leukemia, colon, breast and prostate cancers
  • Fighting obesity
  • Treating immune disorders in humans, including multiple sclerosis, lupus, diabetes mellitus, host-versus-graft reaction and organ transplant rejection
  • Treating inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
  • Extremely effective in increasing bone density without affecting serum calcium levels
  • Compound may be administered in many forms
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.